Selinexor: Targeting a novel pathway in multiple myeloma

Abstract Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to the cytoplasm, including tumour supp...

詳細記述

書誌詳細

出版年:	eJHaem
主要な著者:	Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2023-08-01
主題:	multiple myeloma nuclear export refractory relapsed selective inhibitor of nuclear export targeted therapy
オンライン･アクセス:	https://doi.org/10.1002/jha2.709